Abiomed
This article was originally published in The Gray Sheet
Executive Summary
Firm nets approximately $95 mil. in secondary offering of 1.5 mil. shares at $68 per share. Proceeds will be used primarily to fund initial clinical trials of the AbioCor implantable replacement heart (1"The Gray Sheet" Jan. 10, p. 10). Underwriters include Banc of America Securities and Salomon Smith Barney